Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Heart and Blood Diseases

Substance Related Disorders

Wounds and Injuries

Rare Diseases

Lymphoma

Lymphoma, Non-Hodgkin

Systolic Murmurs

Cardiotoxicity

Hodgkin Disease

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Heart Diseases

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

Radiation Injuries

Lymphosarcoma

Hodgkin Lymphoma

All Drugs and Chemicals

Fluorodeoxyglucose F18

The patient participating in the study needs to respect a minimum of 12-hour fasting period, a high protein and a low-carbohydrate diet prior to performing PET/CT in order to limit physiological 18F-FDG myocardial fixation.

intervention

Stephane EDERHY, Dr

Ariel COHEN, PR

Stephane EDERHY

Management of patients with lymphoma is based on the administration of a chemotherapy containing anthracyclines (ATC), and allows cure rates of 65% to 80% at 5 years. The administration of ATCs can lead to an increase in the risk of the Left Ventricular Systolic dysfunction (LVSD) which ranges from 6 to 15% at 1 year, and of heart failure from which impact at 3.5 years can reach 5%. The major issue in the management of this toxicity is the early identification of this population for monitoring and prevention. No pharmacological intervention strategy is currently recommended.

According to the recommendations of the European Society of Cardiology, this identification is based on the measurement of the left ventricular ejection fraction (LVEF) and the overall longitudinal strain (SLG) before and after the last administration of ATC ( at D84 or D126, depending on the duration of the chemotherapy protocol). Recent studies have evaluated the diagnostic performance of earlier strategies highlighting the benefit of SLG measured after 150 mg / m2 of ATC (D42). However, the tools are lacking to detect these patients as close as possible to the onset of ATC, a necessary condition for effective secondary prevention. The hypothesis is that an early assessment of myocardial binding of 18F-FDG, analyzed during the first routine PET / CT scan as part of the assessment of the response to chemotherapy (D42) should verify a population at risk of developing LVSD at 1 year.

This is a study that evaluates the sensitivity of the cardiac uptake of 18F-FDG measured on D42 of the administration of ATCs to identify at 1 year the patients at risk of occurrence of a LVSD defined by a drop of more than 10 units of the LVEF and LVEF \<53%.

Design : A multicentre clinical trial with 11 sites participating in the study.

Sample size : 484 patients

Duration of inclusion: 25 months Patient observation period: 12 months Total duration: 37 months

Assessment :

There is an inclusion visit, then protocol visits at D42, D84 or D126 and at the end of the study (M12).

There is no interim analysis planned. Analyzes will be performed at the end of the test after reviewing the data and freezing the database.

Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG

Evaluation of the cardiac uptake of 18F-FDG measured on Day 42 of the administration of ATCs to identify at 1 year the patients at risk of occurrence of a LVSD defined by a drop of more than 10 units of the LVEF and LVEF \<53%.

SLG change is defined as: difference in SLG measured prior to chemotherapy administration and at the end of chemotherapy (Day 84 or Day 126 depending on the chemotherapy protocol) .

Assistance Publique - Hôpitaux de Paris

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG	NCT04892667	Lymphoma, Non-H... Lymphoma, Hodgk...	intervention	18 Years -	Assistance Publique - Hôpitaux de Paris
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG	NCT04892667	Lymphoma, Non-H... Lymphoma, Hodgk...	intervention	18 Years -	Assistance Publique - Hôpitaux de Paris
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG	NCT04892667	Lymphoma, Non-H... Lymphoma, Hodgk...	intervention	18 Years -	Assistance Publique - Hôpitaux de Paris

Spots Global Cancer Trial Database for strain longitudinal global (slg)